Trials / Completed
CompletedNCT00241527
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo and Esomeprazole 20 mg Once Daily Versus Placebo in Treatment for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 556 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a treatment period of 4 weeks for relief of upper GI symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole |
Timeline
- Start date
- 2000-12-01
- Primary completion
- 2002-09-01
- Completion
- 2002-09-01
- First posted
- 2005-10-19
- Last updated
- 2011-01-24
Locations
130 sites across 11 countries: United States, Australia, Canada, Czechia, Italy, Norway, Poland, Slovakia, South Africa, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00241527. Inclusion in this directory is not an endorsement.